Targeted Drug Trio Improves Survival in Colorectal Cancer with BRAF Mutations
On behalf of the Journal of Colorectal Cancer: Open Access, as Editor-in-Chief, it is my distinct honour and privilege to inform you that, it’s been Five long years we have started the Journal, now we are celebrating the 5th Anniversary and we are privileged to welcome Cancer Society to our journal. As Editor-In-Chief it is my great pleasure and honour to welcome you to the Journal of Colorectal Cancer: Open Access.
Targeted Drug Trio Improves Survival in Colorectal Cancer with BRAF Mutations this study builds on a decade of research into the tumor biology of BRAF-mutated colorectal cancer and reflects a rational combination to address the vulnerabilities unique to this tumor. New data have shown for the first time that a combination of targeted therapies can improve survival in patients with advanced bowel cancer; these are very exciting results because we’ve been trying to target BRAF-mutant colorectal cancer for many years. It’s encouraging to see such a significant improvement in overall survival and response in patients with such aggressive tumour biology. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation.
The Journal is successfully running in the 5th Volume which covers a wide variety of specialties including BRAF-mutated and gastrointestinal stromal tumour reaching out to research scientists worldwide. The Journal emphasizes high-level research and education. Original research articles, reviews, short communications, and letters to the editors in the fields of Colorectal Cancer are welcome. Every effort is made to have a speedy and critical peer-review process. Realizing the importance of this field, Insight Medical Publishing has organizing a prestigious conference as International Conference on Gastroenterology and Hepatology October 21-22, 2020 Frankfurt, Germany.
The conference is the longest running independent life science events company with a predominantly academic client base. Our multiprofessional and multispeciality approach creates a unique experience that cannot be found with a specialist society or commercially.
Journal of Colorectal Cancer: Open Access
Email id firstname.lastname@example.org